Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


A novel function of p53: a gatekeeper of retinal detachment.

Lei H, Rheaume MA, Cui J, Mukai S, Maberley D, Samad A, Matsubara J, Kazlauskas A.

Am J Pathol. 2012 Sep;181(3):866-74. doi: 10.1016/j.ajpath.2012.05.036.


A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy.

Lei H, Hovland P, Velez G, Haran A, Gilbertson D, Hirose T, Kazlauskas A.

Invest Ophthalmol Vis Sci. 2007 May;48(5):2335-42.


Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Pennock S, Kim D, Mukai S, Kuhnle M, Chun DW, Matsubara J, Cui J, Ma P, Maberley D, Samad A, Van Geest RJ, Oberstein SL, Schlingemann RO, Kazlauskas A.

Am J Pathol. 2013 May;182(5):1659-70. doi: 10.1016/j.ajpath.2013.01.052. Epub 2013 Apr 9.


Elucidation of the pathogenic mechanism of rhegmatogenous retinal detachment with proliferative vitreoretinopathy by proteomic analysis.

Yu J, Peng R, Chen H, Cui C, Ba J.

Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8146-53. doi: 10.1167/iovs.12-10079.


Growth factors outside the PDGF family drive experimental PVR.

Lei H, Velez G, Hovland P, Hirose T, Gilbertson D, Kazlauskas A.

Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3394-403. doi: 10.1167/iovs.08-3042. Epub 2009 Mar 25.


Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy.

Lei H, Rheaume MA, Kazlauskas A.

Exp Eye Res. 2010 Mar;90(3):376-81. doi: 10.1016/j.exer.2009.11.003. Epub 2009 Nov 25. Review.


N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy.

Lei H, Velez G, Cui J, Samad A, Maberley D, Matsubara J, Kazlauskas A.

Am J Pathol. 2010 Jul;177(1):132-40. doi: 10.2353/ajpath.2010.090604. Epub 2010 May 20.


SU9518 inhibits proliferative vitreoretinopathy in fibroblast and genetically modified Müller cell-induced rabbit models.

Velez G, Weingarden AR, Lei H, Kazlauskas A, Gao G.

Invest Ophthalmol Vis Sci. 2013 Feb 19;54(2):1392-7. doi: 10.1167/iovs.12-10320.


Expression of PDGFRα is a determinant of the PVR potential of ARPE19 cells.

Lei H, Rhéaume MA, Velez G, Mukai S, Kazlauskas A.

Invest Ophthalmol Vis Sci. 2011 Aug 24;52(9):5016-21. doi: 10.1167/iovs.11-7442.


Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53.

Lei H, Velez G, Kazlauskas A.

Mol Cell Biol. 2011 May;31(9):1788-99. doi: 10.1128/MCB.01321-10. Epub 2011 Feb 28.


Smad3 is required for dedifferentiation of retinal pigment epithelium following retinal detachment in mice.

Saika S, Kono-Saika S, Tanaka T, Yamanaka O, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, Yoo J, Flanders KC, Roberts AB.

Lab Invest. 2004 Oct;84(10):1245-58.


Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy.

Lei H, Velez G, Hovland P, Hirose T, Kazlauskas A.

Invest Ophthalmol Vis Sci. 2008 Jan;49(1):42-8. doi: 10.1167/iovs.07-0776.


Levels of some cytokines in subretinal fluid in proliferative vitreoretinopathy and rhegmatogenous retinal detachment.

Kenarova B, Voinov L, Apostolov C, Vladimirova R, Misheva A.

Eur J Ophthalmol. 1997 Jan-Mar;7(1):64-7.


Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?

Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A.

Prog Retin Eye Res. 2014 May;40:16-34. doi: 10.1016/j.preteyeres.2013.12.006. Epub 2014 Jan 9. Review.


Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.

Citirik M, Kabatas EU, Batman C, Akin KO, Kabatas N.

Ophthalmic Res. 2012;47(1):7-12. doi: 10.1159/000324200. Epub 2011 Jun 21.


Elevated erythropoietin in vitreous of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.

Wang ZY, Shen LJ, Zhao KK, Song ZM, Qu J.

Ophthalmic Res. 2009;42(3):138-40. doi: 10.1159/000228592. Epub 2009 Jul 15.


A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy.

Pennock S, Rheaume MA, Mukai S, Kazlauskas A.

Am J Pathol. 2011 Dec;179(6):2931-40. doi: 10.1016/j.ajpath.2011.08.043. Epub 2011 Oct 28.


Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.

Pennock S, Haddock LJ, Mukai S, Kazlauskas A.

Am J Pathol. 2014 Nov;184(11):3052-68. doi: 10.1016/j.ajpath.2014.07.026. Epub 2014 Sep 26.


The role of thrombin in proliferative vitreoretinopathy.

Bastiaans J, van Meurs JC, Mulder VC, Nagtzaam NM, Smits-te Nijenhuis M, Dufour-van den Goorbergh DC, van Hagen PM, Hooijkaas H, Dik WA.

Invest Ophthalmol Vis Sci. 2014 Jul 11;55(7):4659-66. doi: 10.1167/iovs.14-14818.


Supplemental Content

Support Center